India, Aug. 25 -- AbbVie, Inc. (ABBV) and Gilgamesh Pharmaceuticals Inc. announced Monday a definitive agreement under which AbbVie will acquire Gilgamesh's lead investigational candidate, Bretisilocin, for up to $1.2 billion, inclusive of an upfront payment and development milestones.
Bretisilocin is currently in clinical development for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
Bretisilocin, a 5-HT2A receptor agonist and 5-HT releaser, is a novel, next-generation psychedelic compound designed to address development challenges observed within this class of compounds. It has been shown to exert a shorter duration of psychoactive experience, while retaining an extended therapeutic benefit.
googleta...